AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia - Concepedia

Concepedia

Publication | Closed Access

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

64

Citations

42

References

2020

Year

Srividya B. Balachander, Steven W. Criscione, Kate F. Byth, Justin Cidado, Ammar Adam, Paula Lewis, Terry Macintyre, Shenghua Wen, Deborah Lawson, Kathleen A. Burke,

Clinical Cancer Research

Abstract

AZD4320 is a potent molecule with manageable thrombocytopenia risk to explore the utility of a dual Bcl-2/Bcl-x<sub>L</sub> inhibitor across a broad range of tumor types with dysregulation of Bcl-2 prosurvival proteins.

References

	Year	Citations

Page 1